Refine by
Ischemic Reperfusion Suppliers & Manufacturers
5 companies found
based inLebanon, NEW HAMPSHIRE (USA)
Celdara Medical gives hope and health to patients by transforming academic innovations into medicines that cure the world’s most challenging diseases. We are a recognized leader with a rich stable of discoveries, developed in concert with premiere ...
Celdara Medical gives hope and health to patients by transforming academic innovations into medicines that cure the world’s most challenging ...
based inSan Diego, CALIFORNIA (USA)
Everyone at AnaBios shares a passion and commitment to make a difference in the development of promising new therapies and cures for patients by reducing the time and expense needed to bring these medicines to patients. We do this by generating ...
The human heart is a complex organ of distinct sub-structures, different tissue types and cellular architectures that work in a coordinated fashion to pump blood throughout the body (Figure 1). Tissue distribution, cellular composition and gene ...
based inYongin, SOUTH KOREA
Bilix is established based on the world’s first PEGylated bilirubin platform technology to produce numerous “First in Class” in anti-inflammatory and “Best in Class” in cancer therapy drugs in addition to achieving other business platform such as ...
Many inflammatory diseases are associated with reactive oxygen species(ROS) in the body. The bilirubin nanoparticle has strong antioxidant, ROS scavenging, and immune modulating properties which effectively eliminate the disease-causing ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
α-Vitamin E ((+)-α-Tocopherol), a naturally occurring vitamin E form, is a potent ...
based inSan Francisco, CALIFORNIA (USA)
ViCardia Therapeutics, Inc., a Delaware corporation, founded in 2017, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for treating heart failure (HF) involving ...
ViCardia is entering Phase 2 with GP531, a potent, long-lasting, infusion therapy that treats mitochondrial dysfunction that leads to chronic heart failure and ultimately to acute decompensated heart failure. ...